CURIS — Curis Lifesciences Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Curis Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 213 | 237 | 354 | 356 | 503 |
| Cost of Revenue | |||||
| Gross Profit | 76.6 | 80.1 | 71.5 | 125 | 184 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 195 | 209 | 329 | 278 | 402 |
| Operating Profit | 18.1 | 28.2 | 25.3 | 77.8 | 101 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 5.62 | 12.3 | 21.7 | 72 | 89.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 5.08 | 4.92 | 18.5 | 50.3 | 62.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 5.08 | 4.92 | 18.5 | 50.3 | 62.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 5.08 | 4.92 | 18.5 | 50.3 | 62.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.705 | 0.609 | 2.29 | 6.22 | 7.67 |